

PROTEIN ALTERNATIVES S.L. ATTENDED

BIO International Convention

Philadelphia, PA from 3rd to 6th June 2018



Photo: partnering meetings at BIO 2018.

PROALT non-invasive test which will allow early detection of colorectal cancer (CCR) in patients affected by this disease, even though clinical symptoms are not visible, is currently being validated clinically, in order to put the product on the market after obtaining the CE mark (IVD). Initially it is planned to be marketed in Europe, the United States, Australia and Canada.

On the therapeutic side, PROALT is advancing the preclinical phase of its therapeutic program with monoclonal antibodies for the treatment of colorectal, breast and melanoma metastatic tumors.

For more information, please contact PROALT: +34 91 804 79 74